spec sheet6 rows
Amibegron approached depression and anxiety from a genuinely unusual angle, agonizing the atypical beta-3 adrenergic receptor rather than touching serotonin transporters or GABA-A directly, on preclinical evidence that beta-3 stimulation increased serotonin and tryptophan levels and blunted stress-induced behavioral changes in rodents. Sanofi-Aventis pushed it all the way to worldwide Phase III trials for both depression and generalized anxiety disorder, a serious late-stage bet on a first-in-class mechanism. The trials came back unconvincing on efficacy, and Sanofi discontinued the program in 2008, leaving beta-3 adrenergic agonism as one of the more interesting mechanistic roads not taken in modern psychopharmacology.
- counteracted stress-induced behavioral and neurochemical changes in rodent models
- increased serotonin release in the prefrontal cortex in preclinical studies
- reached worldwide Phase III trials, a sign of strong early confidence from Sanofi
- Phase III trials in depression and GAD were terminated for lack of sufficient efficacy
- Beta-3 adrenergic receptors are best known today for their role in metabolic drugs for overactive bladder and obesity; amibegron is one of the few compounds that tried to repurpose that same receptor for mood and anxiety.
Mechanism
Selective at the atypical beta-3 receptor (ADRB3); preclinical work showed it increases and tryptophan levels and serotonin release in the prefrontal , distinct from classic monoamine reuptake or receptor-blocking antidepressants.
Safetyrisks and cautions, not medical advice
Few abandoned drugs have been tested this widely. Sanofi ran fourteen Phase III trials covering close to 5,800 patients in depression and generalized anxiety disorder, including a 52-week open-label study of 527 people taking 350 mg twice daily, which is the kind of long-term exposure study a company runs when it expects to file. Nothing in that program was halted for a safety finding; the trials that ended early ended when the efficacy case collapsed. The catch is that none of the fourteen has posted results or produced a published adverse-event table, so the size of the safety database is known and its contents are not.
History
Developed by Sanofi-Aventis; advanced through preclinical rodent stress models into worldwide Phase III trials for depression and generalized anxiety disorder in the mid-2000s. Discontinued in 2008 for lack of demonstrated clinical efficacy.
Subjective profileweighing the evidence above
A legitimately novel adrenergic mechanism for mood and anxiety that made it all the way to Phase III before failing to clear the efficacy bar.
Resources
This entry is here for reference.
Research
1 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
How is amibegron different from an SSRI or SNRI?
It does not inhibit reuptake of serotonin or norepinephrine at all; instead it stimulates the atypical beta-3 adrenergic receptor, which indirectly increased serotonin release in preclinical models.
Why did Sanofi stop developing amibegron?
Phase III trials for both depression and generalized anxiety disorder failed to demonstrate sufficient efficacy, and Sanofi discontinued the program in 2008.
Adverse effects
- Phase III trials in depression and GAD were terminated for lack of sufficient efficacy
Notes and cautions
- detailed human tolerability data was not widely published after discontinuation